Department of Radiation Oncology, Klinikum rechts der Isar, TU München, Ismaninger Str. 22, 81675, Munich, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.
BMC Cancer. 2019 Jul 29;19(1):742. doi: 10.1186/s12885-019-5970-0.
There are different contouring guidelines for the clinical target volume (CTV) in anal cancer (AC) which vary concerning recommendations for radiation margins in different anatomical regions, especially on inguinal site. PET imaging has become more important in primary staging of AC as a very sensitive method to detect lymph node (LN) metastases. Using PET imaging, we evaluated patterns of LN spread, and examined the differences of the respective contouring guidelines on the basis of our results.
We carried out a retrospective study of thirty-seven AC patients treated with chemoradiation (CRT) who underwent FDG-PET imaging for primary staging in our department between 2011 and 2018. Patients showing PET positive LN were included in this analysis. Using a color code, LN metastases of all patients were delineated on a template with "standard anatomy" and were divided indicating whether their location was in- or out-field of the standard CTV as recommended by the Radiation Therapy Oncology Group (RTOG), the Australasian Gastrointestinal Trials Group (AGITG) or the British National Guidance (BNG). Furthermore, a detailed analysis of the location of LN of the inguinal region was performed.
Twenty-two out of thirty-seven AC patients with pre-treatment PET imaging had PET positive LN metastases, accumulating to a total of 154 LN. The most commonly affected anatomical region was inguinal (49 LN, 32%). All para-rectal, external/internal iliac, and pre-sacral LN were covered by the recommended CTVs of the three different guidelines. Of forty-nine involved inguinal LN, fourteen (29%), seven (14%) and five (10%) were situated outside of the recommended CTVs by RTOG, AGITG and BNG. Inguinal LN could be located up to 5.7 cm inferiorly to the femoral saphenous junction and 2.8 cm medial or laterally to the big femoral vessels.
Pelvis-related, various recommendations are largely consistent, and all LN are covered by the recommended CTVs. LN "misses" appear generally cranially (common iliac or para-aortic) or caudally (inguinal) to the recommended CTVs. The established guidelines differ significantly, particular regarding the inguinal region. Based on our results, we presented our suggestions for CTV definition of the inguinal region. LN involvement of a larger number of patients should be investigated to enable final recommendations.
针对肛门癌(AC)的临床靶区(CTV)有不同的勾画指南,这些指南在不同解剖区域的放射边界建议方面存在差异,尤其是在腹股沟部位。PET 成像在 AC 的初始分期中变得越来越重要,因为它是一种非常敏感的方法,可以检测淋巴结(LN)转移。我们使用 PET 成像评估了 LN 扩散的模式,并根据结果检查了各自勾画指南的差异。
我们对 2011 年至 2018 年在我科接受放化疗(CRT)治疗的 37 例 AC 患者进行了回顾性研究,这些患者均接受了 FDG-PET 成像进行初始分期。对 PET 阳性 LN 患者进行了分析。我们使用颜色代码,在“标准解剖学”模板上对所有患者的 LN 转移进行了勾画,并根据其位置是在标准 CTV 内还是外进行了分类,该标准 CTV 是根据放射治疗肿瘤学组(RTOG)、澳大利亚胃肠肿瘤试验组(AGITG)或英国国家指南(BNG)推荐的。此外,我们还对腹股沟区域 LN 的位置进行了详细分析。
37 例接受治疗前 PET 成像的 AC 患者中有 22 例 PET 阳性 LN 转移,共 154 个 LN。最常受影响的解剖区域是腹股沟(49 个 LN,32%)。所有的直肠旁、髂外/内和骶前 LN 均被三个不同指南的推荐 CTV 所覆盖。在 49 个受累的腹股沟 LN 中,14 个(29%)、7 个(14%)和 5 个(10%)位于 RTOG、AGITG 和 BNG 推荐 CTV 之外。腹股沟 LN 可位于股隐静脉交界处下方 5.7cm 以内,或大股血管内侧或外侧 2.8cm 以内。
盆腔相关的各种建议基本一致,所有 LN 均被推荐的 CTV 覆盖。CTV 内的“遗漏”一般位于CTV 之上(髂总或腹主动脉旁)或之下(腹股沟)。现有的指南差异很大,尤其是在腹股沟区域。基于我们的结果,我们提出了腹股沟区域 CTV 定义的建议。应调查更多患者的 LN 受累情况,以便最终提出建议。